BioVersys AG, a clinical-stage biopharmaceutical company developing novel antibacterials for multidrug-resistant infections, announced the publication of two Phase 1 clinical pharmacology studies of its lead asset BV100 in the International Journal of Antimicrobial Agents and the Journal of Antimicrobial Chemotherapy. The data are important because they strengthen the pharmacological rationale for BV100 in hospital- and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC), a condition with limited treatment options and high mortality.
The first paper, published in the International Journal of Antimicrobial Agents (DOI: 10.1016/j.ijantimicag.2026.108014), reports a lung penetration study in 36 healthy male participants who received intravenous BV100 300 mg every 12 hours for four days. Concentrations of rifabutin in lung fluid and alveolar macrophages exceeded plasma concentrations at every time point, with median penetration ratios of approximately 35-fold and over 300-fold, respectively. Repeated dosing was well tolerated. The authors conclude that these pulmonary exposures provide a strong pharmacological rationale for further clinical evaluation of BV100 in severe CRAB pneumonia.
The second paper, published in the Journal of Antimicrobial Chemotherapy (DOI: 10.1093/jac/dkag317), describes two Phase 1 drug-drug interaction studies. BV100 was shown to be a mild CYP3A inducer, reducing midazolam exposure by approximately 47%, and a mild substrate for CYP3A inhibitors, with rifabutin exposure increasing 1.3- to 1.7-fold with itraconazole. This is a milder interaction profile than that of rifampicin, a strong CYP3A inducer, and BV100 was safe and well tolerated. The milder profile is clinically important because critically ill pneumonia patients often receive multiple concomitant medications.
Dr. Glenn Dale, Chief Development Officer of BioVersys and co-author of the publications, said the papers address the questions that matter most for an intravenous antibiotic in critically ill pneumonia patients, noting that BV100 has very good distribution in lung fluid and alveolar macrophages and a mild, manageable drug-interaction profile. Dr. Marc Gitzinger, Chief Executive Officer and founder, added that carbapenem-resistant Acinetobacter baumannii represents one of the highest medical needs in infectious disease and that these data continue to strengthen the scientific basis for BV100 therapy in CRABC pneumonia.
Both Phase 1 datasets form part of the clinical pharmacology foundation of RIV-TARGET, the ongoing Phase 3 registration trial of BV100 in HABP and VABP caused by CRABC. Enrollment is ongoing, with topline data anticipated in early 2028. BV100 is also being studied in the open-label Phase 2b differentiation trial, RIV-CARE, in collaboration with ADVANCE-ID. In September 2026, BV100 received Fast Track Designation from the US FDA under the Qualified Infectious Disease Product designation granted in 2019, making it eligible for priority review and a five-year extension of market exclusivity upon approval of the first QIDP indication.
The publications matter because CRABC infections are among the most resistant hospital pathogens, with incidence and resistance rates trending upward and mortality rates up to 50%. BioVersys forecasts that annual carbapenem-resistant A. baumannii infections in hospitals have surpassed one million globally. With few treatment options, a novel intravenous rifabutin formulation that achieves high lung exposures and has a manageable interaction profile could offer a much-needed option for critically ill patients if the Phase 3 program confirms these findings.
